1. Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma 
Jessica Rueff, Michael Medinger, Dominik Heim, Jakob Passweg, Martin Stern 
Biology of Blood and Marrow Transplantation 
Volume 20, Issue 6, Pages (June 2014)
DOI: /j.bbmt
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Reconstitution of lymphocyte subsets (CD8 T cells [CD8+/CD3+], CD4 T cells [CD4+/CD3+], natural killer cells [CD56+/CD16+/CD3−], and B cells [CD19+]) after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Curves represent means ± standard errors of the mean, and gray areas represent the range of healthy donor normal values.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Rates of progression-free survival (A), time to next antimyeloma treatment (B), and overall survival (C) in patients treated with autologous HSCT for plasma cell myeloma. Patients are grouped by their NK cell count at day 30 after autologous HSCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions